Goldman Sachs

Xiaomi Corp may have raised a little less than expected in its much-hyped Hong Kong debut, but China Tower Corp is ready to steal the thunder with a juicy $10bn IPO.

The State of North Rhine-Westphalia has launched its first ever 50 year benchmark, coming to market just as Bank Nederlandse Gemeenten landed at the short end.

Bio-technology firms AOBiome Therapeutics and Stealth Biotherapeutics Corp are seeking the greenlight to float in Hong Kong, adding to a fast-growing pipeline from the sector.

The State of North Rhine-Westphalia is set to bring its longest ever euro benchmark, as public sector borrowers line up trades across the currency’s curve.

Pinduoduo, one of China’s hottest internet start-ups, has filed for a $1bn IPO in the US, upping the ante in an e-commerce landscape dominated by Alibaba Group.

Asia’s G3 bond market has been defined by volatility this year, forcing bankers, investors and issuers alike to think on their feet during the first half of 2018. As banks fight to stay on top of the limited primary market activity, the region’s league tables have been disrupted.

Udhay Furtado has left Goldman Sachs after 12 years with the US bulge bracket firm to take up a new role at Citi.

French car parts distributor Autodis announced an add-on of its only floating rate bond on Monday, amid higher average high yield funding costs but with investors confident that the market can cope.

Voters rewarded a five year dollar print from Finnvera — the first in that tenor from a European SSA since March — with strong scores across the board.

Deutsche Bank shares were up nearly 4% on Friday morning, following confirmation on Thursday evening that the Federal Reserve had failed the Comprehensive Capital Analysis and Review submission from its DB USA unit on qualitative grounds. The Fed also blocked planned payout boosts from Goldman Sachs and Morgan Stanley.

China Tower Corp is set to begin premarketing its Hong Kong IPO next week, after winning listing approval on Thursday for what is expected to be a $10bn deal, according to a source close to trade.

Hong Kong’s new biotechnology-friendly listing regime attracted IPO filings this week from China-based Innovent Biologics and MicuRx Pharmaceuticals.